Ankit Kalucha (@Ankitowledge) header
Ankit Kalucha (@Ankitowledge) profile picture

Ankit Kalucha

@Ankitowledge

Easing oncology outcomes decision making

 India
clin.larvol.com/all-data
Joined December 2023
  • Tweets45
  • Following463
  • Followers51
13Media
Photo by Ankit Kalucha (@Ankitowledge)Photo by Ankit Kalucha (@Ankitowledge)Photo by Ankit Kalucha (@Ankitowledge)Photo by Ankit Kalucha (@Ankitowledge)Photo by Ankit Kalucha (@Ankitowledge)Photo by Ankit Kalucha (@Ankitowledge)Photo by Ankit Kalucha (@Ankitowledge)Photo by Ankit Kalucha (@Ankitowledge)Photo by Ankit Kalucha (@Ankitowledge)Photo by Ankit Kalucha (@Ankitowledge)
AI Derived Emerging Targets at ESMO 2026 #oncology #CancerCare #esmo #HealthcareAI
🤖 Made with AI
Image from Ankit Kalucha (@Ankitowledge)
1
47
The other side of ASCO 2026. Used Gen AI to synthesize ASCO 2026 KOL negative commentary into a simple signal map.
Image from Ankit Kalucha (@Ankitowledge)
Image from Ankit Kalucha (@Ankitowledge)
Image from Ankit Kalucha (@Ankitowledge)
1
5
6
1,063
Ankit Kalucha retweeted
ASCO (@ASCO) profile picture
ASCO
@ASCO22 Aug 2025
NEW ASCO Guidelines Assistant tool leverages Google Cloud Vertex AI platform & Gemini models, enabling oncology clinicians to quickly access evidence-based clinical guidelines.

2
48
4
297
482,438
Immune cell effector-associated neurotoxicity syndrome (ICANS) is a less well understood entity related to cytokine disruption of BBB and comprising diverse neurological symptoms. ICANS was rare (<10%) and no ICANS 3 or more was observed. (pic from Sands Cancer 2024) 🧵12/15
Image from Giannis Mountzios (@g_mountzios)
1
1
3
428
Do ΔORR and ΔDoR Predict PFS and OS Hazard Ratios Across Cancer RCTs? #CancerTrials #RCTs #MedicalAI
Image from Ankit Kalucha (@Ankitowledge)
2
68
Deep research cost evaluation of the recent Stage IV NSCLC With Driver Alterations: ASCO Living Guideline v2024.3 #nsclc #ASCO #lungcancer #Oncology
Image from Ankit Kalucha (@Ankitowledge)
2
114
#checkmate274 Deep Research
Image from Ankit Kalucha (@Ankitowledge)
1
3
239
SWOT by Deep Research. Potential SOC SERENA 6.
Image from Ankit Kalucha (@Ankitowledge)
1
1
10
772
Image from Ankit Kalucha (@Ankitowledge)
3
71
Generative Reward Models Self-Taught Reasoning (STAR) in AI Training for cancer clinical trials
Image from Ankit Kalucha (@Ankitowledge)
1
3
97
Mixture-of-experts Concepts
Image from Ankit Kalucha (@Ankitowledge)
3
73
Image from Ankit Kalucha (@Ankitowledge)
3
56
Biomarkers, Molecular Targets, and Methods of Detection for Precision Medicines in NSCLC (ESMO guideline)
Image from Yakup Ergün (@dr_yakupergun)
53
1
158
21,223
🫁 NCCN guideline updated 🫁 🫁 Part-1, NSCLC 🫁 🌟 Version 9.2024 — September 9, 2024 🌟 📌 Ver. 8 was updated on August 23, 2024, so went to ver. 9 in about 2 weeks, right in the middle of WCLC 2024.
Image from Katsuaki Maehara 🇯🇵 (@KatsuakiMaehara)
Image from Katsuaki Maehara 🇯🇵 (@KatsuakiMaehara)
1
13
1
50
4,671
Ankit Kalucha retweeted
ONCO BRUNO (@brunolarvol) profile picture
ONCO BRUNO
@brunolarvol11 Sep 2024
#WCLC24 @IASLC was a joy. Thank @one_interrobang @donnashort @marklewismd @HHorinouchi and all
2
8
1
15
635
🫁 Lung Cancer - ICIs data 🫁 🌟 Summary of 5-year (long follow-up) data 🌟 NSCLC (NSQ & SQ) #Immunotherapy #Lungcancer #longfollowup #LCSM
Image from Katsuaki Maehara 🇯🇵 (@KatsuakiMaehara)
1
75
1
215
31,395
Ankit Kalucha retweeted
Juan Sequeda (@juansequeda) profile picture
Juan Sequeda
@juansequeda2 Aug 2024
Seems like Ontologies are back - 20 years ago, ontologies were gaining traction. W3C OWL became a standard - 10 years ago it was a red flag. Don’t say the “o word” - Now w/ LLMs, we have the need to manage knowledge in a structured & governed manner What comes around, goes around
8
28
6
112
6,532
🎯PFS-2 is a better surrogate for OS than PFS in advanced cancer trials 🔥 👉 PFS-2 has a stronger correlation with OS benefit (r = 0.70 vs r = 0.46) 🤔Should PFS-2 be the primary endpoint in future trials??? @ASCO @myESMO @eaonc @SWOG @EORTC @VPrasadMDMPH @VincentRK #PFS2 #OS #CancerResearch ascopubs.org/doi/10.1200/PO.…
Image from Yüksel Ürün (@DrYukselUrun)
6
41
4
125
27,062
Summary of 5 new drugs/indications in GI malignancies that were @FDAOncology @US_FDA approved in 2023: - #Tucatinib - Mountaineer - #TAS102 + #Bevacizumab - Sunlight - #Pembro + Cis/Gem - KN966 - #Fruquintinib - FRESCO2 - #Pembro + Chemo - KN859 #OncTwitter #gism #crcsm
Image from Oncology Brothers (@OncBrothers)
Oncology Brothers (@OncBrothers) profile pictureOncology Brothers
@OncBrothers24 Dec 2022
Summary of the 4 new drugs/indications that were approved for GI malignancies by @FDAOncology in 2022: - Nivo & Ipi/Nivo - Durvalumab - Futibatinib - Treme + Durva #GastricCancer #MedEd @OncoAlert @ASCO #GIOncology #CRCSM #MedTwitter #OncTwitter #Oncology #gism
Image from Oncology Brothers (@OncBrothers)
2
55
2
126
56,853
🎆🎯2023 FDA approvals. 👉🏼The FDA approved 55 novel therapeutics in 2023, the second highest count in the past 30 years 🙌🏼 👍🏼The FDA’s Center for Drug Evaluation and Research (CDER) approved 55 new drugs in 2023, as the small molecule and biologic pharmacopoeia continues to grow @tmprowell @FDAOncology @US_FDA @OncoAlert @NatRevDrugDisc @statnews nature.com/articles/d41573-0…
Image from Vivek Subbiah, MD (@VivekSubbiah)
27
1
59
10,162
Load more